Bayer and Soufflé Therapeutics announced a global licensing agreement to develop an siRNA-based therapy for dilated cardiomyopathy, a form of heart disease.
Soufflé Therapeutics closed a $135 million Series B financing round led by Juvia Group and including investors such as TCG Crossover Management, BB Biotech, Fidelity Management & Research Company, and Balyasny Asset Management.
Founded and led by some of the greatest minds in genetic medicine, Soufflé has brought together a team of experts who share a passion for the relentless pursuit of safer, stronger and more durable medicines.
Soufflé Therapeutics secures a $135 million Series B funding round, led by Juvia Group and joined by investors including TCG Crossover Management, BB Biotech, and Fidelity Management & Research Company. The capital will accelerate its lead RNA therapy clinical programs and support ongoing pipeline development. The round exceeds expectations, indicating strong investor confidence in the company’s approach to next-generation therapeutic solutions.
